Topic: Tackling the Challenge of Drug Resistance in Lung Cancer

Lung cancer remains a significant global health challenge, where overcoming drug resistance poses a formidable obstacle to effective treatments. This Special Issue aims to highlight the intricate landscape of drug resistance in lung cancer. It encompasses investigations into genetic, molecular, and metabolic mechanisms, with a special focus on combating drug resistance in the treatment of non-small cell lung cancer. This collection serves as a platform for researchers to share their breakthroughs, present novel hypotheses, and provide critical analyses that propel the field forward. By fostering a deeper understanding of lung cancer drug resistance, we aim to inspire the development of transformative therapeutic strategies that could ultimately improve patient outcomes and quality of life.

The topics covered include, but are not limited to:

1. The molecular and metabolic pathways that enable tumor cells to evade chemotherapy-induced cytotoxicity;

2. Mechanisms underlying resistance to immune checkpoint inhibitors and other immunotherapies in lung cancer;

3. Resistance mechanisms in lung cancer patients treated with tyrosine kinase inhibitors (TKIs);

4.Tumor heterogeneity and emergence of resistant clones: impact on the therapeutic response in lung cancer patients；

   etc.